Efficacy of combination therapy with erlotinib and vemurafenib. The combination of an EGFR targeted monoclonal antibody (cetuximab) and BRAF (vemurafenib) inhibition had shown efficacy in colon cancer cells with BRAF mutation [15]. Here, BRAF is linked to colonic neoplasm.